ArticleBMC pediatrics2026
Rare presentation of serous effusions in pediatric acute myeloid leukemia: insights from a retrospective case series.
Article in BMC pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundSerous effusions are rare extramedullary manifestations of pediatric acute myeloid leukemia (AML), for which limited data are available. This study aimed to systematically characterize the clinical features, biological profiles, and outcomes of pediatric AML patients who presented with serous effusions.
methodsA retrospective case series was conducted at Beijing Children’s Hospital and Beijing Children’s Hospital Baoding Hospital from January 2015 to December 2024. Pediatric patients newly diagnosed with AML or isolated myeloid sarcoma presenting with serous effusion were included.
resultsSeven children (six males and one female) were included. The median time from symptom onset to diagnosis was 30 days (range: 10–150 days). Initial white blood cell counts ranged from 3.39 × 10⁹/L to 212.13 × 10⁹/L, with two patients exhibiting hyperleukocytosis. Genetic alterations included KMT2A rearrangements (4/7), RUNX1::RUNX1T1 fusions (2/7), and SFPQ::ZFP36L2 fusion (1/7). All patients had pleural effusions, and six had pericardial effusion. Four patients had additional extramedullary involvement. The median follow-up was 12.0 months (range: 1.0–68.0 months). Owing to critical illness, six of the seven patients received induction therapy in the intensive care unit. One patient died after induction therapy because of severe acute suppurative appendicitis and sepsis; the remaining six patients underwent hematopoietic stem cell transplantation. At the last follow-up, four patients were alive, while two died of early relapse following stem cell transplantation.
conclusionsSerous effusion is a rare manifestation of pediatric AML, which is observed in patients with high-risk genetics and is often accompanied by a critical clinical course necessitating intensive care. Further studies are needed in this subgroup.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.